A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein

Aimin Tang; Zhifeng Chen; Kara S. Cox; Hua-Poo Su; Cheryl Callahan; Arthur Fridman; Lan Zhang; Sangita B. Patel; Pedro J. Cejas; Ryan Swoyer; Sinoeun Touch; Michael Citron; Dhanasekaran Govindarajan; Bin Luo; Michael J. Eddins; John C. Reid; S.M. Soisson; Jennifer Galli; Dai Wang; Zhiyun Wen; Gwendolyn J. Heidecker; Danilo R. Casimiro; Daniel J. DiStefano; Kalpit A. Vora

doi:10.1038/s41467-019-12137-1

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein

Aimin Tang(United States Military Academy), Zhifeng Chen(United States Military Academy), Kara S. Cox(United States Military Academy), Hua-Poo Su(United States Military Academy), Cheryl Callahan(United States Military Academy), Arthur Fridman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lan Zhang(United States Military Academy), Sangita B. Patel(United States Military Academy), Pedro J. Cejas(United States Military Academy), Ryan Swoyer(United States Military Academy), Sinoeun Touch(United States Military Academy), Michael Citron(United States Military Academy), Dhanasekaran Govindarajan(Janssen (Belgium)), Bin Luo(United States Military Academy), Michael J. Eddins(United States Military Academy), John C. Reid(United States Military Academy), S.M. Soisson(United States Military Academy), Jennifer Galli(United States Military Academy), Dai Wang(United States Military Academy), Zhiyun Wen(United States Military Academy), Gwendolyn J. Heidecker(United States Military Academy), Danilo R. Casimiro(United States Military Academy), Daniel J. DiStefano(United States Military Academy), Kalpit A. Vora(Merck & Co., Inc., Rahway, NJ, USA (United States))

Nature Communications

September 12, 2019

10.1038/s41467-019-12137-1

Cited by 150Open Access

Full Text

Abstract

Respiratory syncytial virus (RSV) infection is the leading cause of hospitalization and infant mortality under six months of age worldwide; therefore, the prevention of RSV infection in all infants represents a significant unmet medical need. Here we report the isolation of a potent and broadly neutralizing RSV monoclonal antibody derived from a human memory B-cell. This antibody, RB1, is equipotent on RSV A and B subtypes, potently neutralizes a diverse panel of clinical isolates in vitro and demonstrates in vivo protection. It binds to a highly conserved epitope in antigenic site IV of the RSV fusion glycoprotein. RB1 is the parental antibody to MK-1654 which is currently in clinical development for the prevention of RSV infection in infants.

Related Papers

No related papers found

Powered by citation graph analysis